Selective administration of prophylactic octreotide during pancreaticoduodenectomy: a clinical and cost-benefit analysis in low- and high-risk glands.

Published on Oct 1, 2007in Journal of The American College of Surgeons4.45
· DOI :10.1016/j.jamcollsurg.2007.05.011
Tsafrir Vanounou6
Estimated H-index: 6
(BIDMC: Beth Israel Deaconess Medical Center),
Wande B. Pratt17
Estimated H-index: 17
(BIDMC: Beth Israel Deaconess Medical Center)
+ 1 AuthorsCharles M. Vollmer40
Estimated H-index: 40
(BIDMC: Beth Israel Deaconess Medical Center)
Background The efficacy of prophylactic octreotide after pancreaticoduodenectomy has been rigorously scrutinized, yet few studies have specifically illustrated its impact in patients at high risk for pancreatic fistula. Applying a previously validated clinical classification scheme (International Study Group on Pancreatic Fistula) for postoperative pancreatic fistula severity, we examined whether prophylactic octreotide could effectuate a clinical or fiscal benefit, or both, after pancreatic resection. Study Design There were 227 consecutive patients who underwent pancreaticoduodenectomy from October 2001 to January 2007. At the surgeon's discretion, prophylactic octreotide was administered intraoperatively and continued postoperatively. Clinically relevant fistulas, requiring therapeutic interventions or resulting in severe clinical sequelae, were identified, as were other complications. Through multivariate analysis, risk factors for fistula were defined as soft gland texture; small duct size; ampullary, duodenal, cystic, or islet cell pathology; and increased blood loss. Beyond a traditional review of clinical outcomes, a novel economic cost-benefit analysis of octreotide prophylaxis was performed, with concentration of impact on high-risk glands (one or more risk factors). Results Overall, 55% of patients had at least one risk factor. Clinically relevant fistulas were present in 14.9% of all patients. High-risk glands resulted in significantly worse clinical and economic outcomes compared with low-risk glands (no risk factors present). Prophylactic octreotide in low-risk glands was neither clinically effective nor cost efficient after pancreaticoduodenectomy, contributing to 781 in overspending per patient—approximately equivalent to a 7-day postoperative course of octreotide. But in patients with high-risk glands, octreotide prophylaxis was associated with a decreased incidence (20% versus 35%) and morbidity of clinically relevant fistulas. These improved clinical outcomes were associated with reduced resource use, translating to considerable cost savings (1,849) per high-risk patient. Conclusions Octreotide prophylaxis is an effective approach to mitigate the negative impact of pancreatic fistulas, but to obtain maximal clinical value and cost benefit, octreotide should be administered exclusively to patients with high-risk glands.
  • References (38)
  • Citations (42)
📖 Papers frequently viewed together
2,877 Citations
213 Citations
251 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Tsafrir Vanounou (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 6
#2Wande B. Pratt (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 17
Last. Mark P. Callery (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 48
view all 5 authors...
Background Although clinical pathways were developed to streamline patient care cost efficiently, few have been put to rigorous financial test. This is important today, because payors demand clear solutions to the cost-quality puzzle. We describe a novel, objective, and versatile model that can evaluate and link the clinical and economic impacts of clinical pathways. Study Design Outcomes for 209 consecutive patients undergoing high-acuity surgery (pancreaticoduodenectomy), before and after path...
79 CitationsSource
#1Wande B. PrattH-Index: 17
#2Shishir K. MaithelH-Index: 38
Last. Charles M. VollmerH-Index: 40
view all 6 authors...
Pancreatic fistula is widely regarded as the most ominous of complications following pancreatic resection. Its clinical impact and sequelae have been previously described and shown to contribute to the development of other morbid complications and high rates of mortality.1–4 Despite refinements in operative technique and advancements in postoperative management, fistulas still occur with a frequency of 5% to 30%.5–12 Efforts to mitigate this problem have included technical considerations (modifi...
251 CitationsSource
#1Michelle L. DeOliveira (Johns Hopkins University)H-Index: 15
#2Jordan M. Winter (Johns Hopkins University)H-Index: 36
Last. P.-A. Clavien (UZH: University of Zurich)H-Index: 97
view all 7 authors...
Mortality associated with pancreaticoduodenectomy (PD) has decreased dramatically to less than 5% over the past 2 decades in high-volume centers,1–6 but persistent high morbidity rates have remained an important concern for patients, healthcare providers, and payers. While mortality is an objective and easily quantifiable outcome parameter, morbidity is only poorly defined, and this shortcoming has severely hampered conclusive comparisons among centers and within the same institution over time.7...
543 CitationsSource
#1Wande B. Pratt (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 17
#2Shishir K. Maithel (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 38
Last. Charles M. Vollmer (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 40
view all 5 authors...
It is uncertain whether postoperative pancreatic fistulas after distal and central pancreatectomies behave similarly to those after pancreaticoduodenectomy. To date, this concept has not been validated either clinically or economically. Overall, 256 consecutive pancreatic resections from October 2001 to February 2006 (184 pancreaticoduodenectomies, 66 distal pancreatectomies, and 6 central pancreatectomies) were evaluated according to the International Study Group of Pancreatic Fistula classific...
88 CitationsSource
#1John L. Cameron (Johns Hopkins University)H-Index: 118
#2Taylor S. Riall (Johns Hopkins University)H-Index: 35
Last. Kenneth A. Belcher (Johns Hopkins University)H-Index: 1
view all 4 authors...
The first successful local resection of a periampullary tumor was performed by Dr. William Stewart Halsted in 1898.1 The patient was a 58-year-old woman with obstructive jaundice. Halsted resected a segment of the second portion of the duodenum, including the tumor, and anastomosed the duodenum end to end. He then reimplanted the bile and pancreatic ducts. The first successful regional resection for a periampullary tumor was performed by the German surgeon from Berlin, Kausch, in 1909, and repor...
852 CitationsSource
Background/Purpose The Achilles' heel of operative pancreatectomies is the pancreaticoenterostomy for proximal resections and the pancreatic parenchymal closure for distal resections. Inhibition of pancreatic exocrine secretions by somatostatin analogues has been suggested to decrease pancreas-specific complications, but this topic remains controversial.
28 CitationsSource
#1T. Foitzik (University of Rostock)H-Index: 1
#2Michael Gock (University of Rostock)H-Index: 11
Last. ErnstKlar (University of Rostock)H-Index: 39
view all 5 authors...
Background and aims Leakage from pancreaticojejunostomy and development of pancreatic fistulas are the major postoperative complications in patients undergoing duodenopancreatectomy. The risk of developing these complications is higher when surgery is performed on a soft pancreas. A recent report suggests that octreotide hardens the pancreas when given intraoperatively. The present study aims at verifying this observation by measuring tissue hardness of the pancreas by a commercially available d...
12 CitationsSource
#1Claudio Bassi (University of Verona)H-Index: 80
#2Christos DervenisH-Index: 45
Last. Markus W. Büchler (University Hospital Heidelberg)H-Index: 127
view all 10 authors...
Background Postoperative pancreatic fistula (POPF) is still regarded as a major complication. The incidence of POPF varies greatly in different reports, depending on the definition applied at each surgical center. Our aim was to agree upon an objective and internationally accepted definition to allow comparison of different surgical experiences. Methods An international panel of pancreatic surgeons, working in well-known, high-volume centers, reviewed the literature on the topic and worked toget...
2,877 CitationsSource
#1Choon-Kiat Ho (Heidelberg University)H-Index: 3
#2Jörg Kleeff (Heidelberg University)H-Index: 70
Last. Markus W. Büchler (Heidelberg University)H-Index: 127
view all 4 authors...
Pancreatic resection is the only treatment option that can lead to a meaningful prolonged survival in pancreatic cancer and, in some instances, perhaps a potential chance for cure. With the advent of organ and function preserving procedures, its use in the treatment of chronic pancreatitis and other less common benign diseases of the pancreas is increasing. Furthermore, over the past two decades, with technical advances and centralization of care, pancreatic surgery has evolved into a safe proce...
94 CitationsSource
Background and Objectives Leakage from the pancreaticojujenostomy is the most serious complication of Whipple. Pancreatic fistula rate is higher in cases of fragile pancreas often seen in duodenal carcinomas and carcinomas of the ampulla of Vater. Octreotide administration has been used for the prevention of fistula formation through the subcutaneous route. Due to its physiologic effects to the pancreatic parenchyma the intra-arterial administration of octreotide could provide tissue hardening t...
14 CitationsSource
Cited By42
#1Jian Lin (Fujian Medical University)
#2Biqing Ni (Fujian Medical University)
Last. Guozhong Liu (Fujian Medical University)
view all 3 authors...
AbstractPurpose: This study aimed to evaluate the efficacy of percutaneous endoscopic necrosectomy (PEN) combined with percutaneous catheter drainage (PCD) and irrigation versus PCD for the treatme...
#1Emanuel Eguia (Loyola University Medical Center)H-Index: 1
#2Paul C. Kuo (USF: University of South Florida)H-Index: 57
Last. Marshall S. Baker (Loyola University Medical Center)
view all 8 authors...
Abstract Background Little is known regarding the impact of minimally invasive approaches to pancreatoduodenectomy on the aggregate costs of care for patients undergoing pancreatoduodenectomy. Methods We queried the Healthcare Cost and Utilization Project State Inpatient Database to identify patients undergoing elective laparoscopic or open pancreatoduodenectomy between 2014 and 2016. Results In this database, 488 (10%) patients underwent elective laparoscopic; 4,544 (90%) underwent open pancrea...
#1Wonju Hong (Sacred Heart Hospital)H-Index: 1
#2Hong Il Ha (Sacred Heart Hospital)H-Index: 4
Last. Min-Jeong Kim (Sacred Heart Hospital)H-Index: 2
view all 5 authors...
1 CitationsSource
#1Jason WangH-Index: 1
#2Laurence WeinbergH-Index: 17
#1Jason Wang (Austin Hospital)H-Index: 1
#2Ronald Ma (Austin Hospital)H-Index: 1
Last. Laurence Weinberg (University of Melbourne)H-Index: 17
view all 7 authors...
Abstract Background/Objectives Pancreaticoduodenectomy (PD), also known as a Whipple procedure, is commonly performed for a variety of benign and malignant tumours, including of the pancreatic head and surrounding structures. PD is associated with low mortality but high morbidity and costs. Our objective was to describe the financial burden of complications following pancreaticoduodenectomy. Methods We searched for articles using the MEDLINE, EMBASE, Cochrane and EconLit databases from the year ...
5 CitationsSource
#1Christopher R. Shubert (Mayo Clinic)H-Index: 9
#2Michael L. Kendrick (Mayo Clinic)H-Index: 45
Last. Florencia G. Que (Mayo Clinic)H-Index: 46
view all 12 authors...
Abstract Background Morbidity and costs after pancreatoduodenectomy remain increased, driven by postoperative pancreatic fistula (POPF). A risk-based pathway for pancreatoduodenectomy (RBP-PD) was implemented and the clinical and cost outcomes compared with that of our historic practice. Methods Prospective clinical and cost outcomes for our RBP-PD cohort treated from September 2014 to September 2015 were compared with a previously published cohort of pancreatoduodenectomies from January 2007 to...
#1Hangyan WangH-Index: 2
#2Dianrong XiuH-Index: 6
Last. Ming TaoH-Index: 4
view all 3 authors...
2 CitationsSource
#1Linda MaH-Index: 1
Last. Peter J. AllenH-Index: 68
view all 11 authors...
Objective:The objective of this study was to determine the costs of clinically significant postoperative pancreatic fistula (POPF) and to evaluate the cost-effectiveness of routine pasireotide use.Summary of Background Data:We recently completed a prospective randomized trial that demonstrated an 11
20 CitationsSource
#1Yasmine Assadipour (NIH: National Institutes of Health)H-Index: 4
#2Saïd C. Azoury (NIH: National Institutes of Health)H-Index: 1
Last. Marybeth S. Hughes (NIH: National Institutes of Health)H-Index: 33
view all 10 authors...
Abstract Background Postoperative pancreatic fistula remains the most severe and worrisome complication after surgery. Predictive preoperative assessment remains challenging. The authors examine the role of pancreatic computed tomography density in predicting postoperative pancreatic fistula after surgery for pancreatic neuroendocrine tumors. Methods A single institutional retrospective review of pancreatic surgery for neuroendocrine tumors between 1998 and 2010 was conducted. Preoperative contr...
1 CitationsSource